Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

The current role and future prospects of D-dimer biomarker.

Soomro AY, Guerchicoff A, Nichols DJ, Suleman J, Dangas GD.

Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):175-84. doi: 10.1093/ehjcvp/pvv039. Epub 2015 Sep 27. Review.

PMID:
27533759
2.

Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial.

Guerchicoff A, Stone GW, Mehran R, Xu K, Nichols D, Claessen BE, Guagliumi G, Witzenbichler B, Henriques JP, Dangas GD.

Catheter Cardiovasc Interv. 2015 Feb 15;85(3):335-42. doi: 10.1002/ccd.25620. Epub 2014 Nov 10.

PMID:
25130788
3.

Impact of pre-procedural cardiopulmonary instability in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial).

Brener SJ, Brodie BR, Guerchicoff A, Witzenbichler B, Guagliumi G, Xu K, Mehran R, Stone GW.

Am J Cardiol. 2014 Oct 1;114(7):962-7. doi: 10.1016/j.amjcard.2014.07.004. Epub 2014 Jul 16.

PMID:
25118121
4.

Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction).

Guerchicoff A, Brener SJ, Maehara A, Witzenbichler B, Fahy M, Xu K, Gersh BJ, Mehran R, Gibson CM, Stone GW.

JACC Cardiovasc Interv. 2014 Jul;7(7):733-40. doi: 10.1016/j.jcin.2014.01.166.

5.

Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial.

Brener SJ, Dizon JM, Mehran R, Guerchicoff A, Lansky AJ, Farkouh M, Brodie B, Guagliumi G, Witzenbichler B, Fahy M, Parise H, Stone GW.

Am Heart J. 2013 Oct;166(4):676-83. doi: 10.1016/j.ahj.2013.07.025. Epub 2013 Sep 13.

PMID:
24093847
6.

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.

Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators.

Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26. Erratum in: Lancet. 2014 Mar 29;383(9923):1128.

PMID:
23890998
7.

Impact of scheduled angiographic follow-up in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Mindrescu C, Brener SJ, Guerchicoff A, Fahy M, Parise H, Mehran R, Stone GW.

J Interv Cardiol. 2013 Aug;26(4):319-24. doi: 10.1111/joic.12038. Epub 2013 Jun 24.

PMID:
23795656
8.

Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant.

Crotti L, Hu D, Barajas-Martinez H, De Ferrari GM, Oliva A, Insolia R, Pollevick GD, Dagradi F, Guerchicoff A, Greco F, Schwartz PJ, Viskin S, Antzelevitch C.

Heart Rhythm. 2012 Jul;9(7):1104-12. doi: 10.1016/j.hrthm.2012.02.014. Epub 2012 Feb 13.

9.

Susceptibility genes for coronary heart disease and myocardial infarction.

Kibos A, Guerchicoff A.

Acute Card Care. 2011 Sep;13(3):136-42. doi: 10.3109/17482941.2011.606477. Review.

PMID:
21877873
10.

Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death.

Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpón E, Hu D, Desai M, Borggrefe M, Häissaguerre M, Kanter R, Pollevick GD, Guerchicoff A, Laiño R, Marieb M, Nademanee K, Nam GB, Robles R, Schimpf R, Stapleton DD, Viskin S, Winters S, Wolpert C, Zimmern S, Veltmann C, Antzelevitch C.

Heart Rhythm. 2010 Dec;7(12):1872-82. doi: 10.1016/j.hrthm.2010.08.026. Epub 2010 Oct 14.

11.

An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing.

Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, Fressart V, Guerchicoff A, Harris-Kerr C, Kamakura S, Kyndt F, Koopmann TT, Miyamoto Y, Pfeiffer R, Pollevick GD, Probst V, Zumhagen S, Vatta M, Towbin JA, Shimizu W, Schulze-Bahr E, Antzelevitch C, Salisbury BA, Guicheney P, Wilde AA, Brugada R, Schott JJ, Ackerman MJ.

Heart Rhythm. 2010 Jan;7(1):33-46. doi: 10.1016/j.hrthm.2009.09.069. Epub 2009 Oct 8.

12.

A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype.

Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A, Pfeiffer R, Koopmann TT, Cordeiro JM, Guerchicoff A, Pollevick GD, Antzelevitch C.

Circ Cardiovasc Genet. 2009 Jun;2(3):270-8. doi: 10.1161/CIRCGENETICS.108.829192. Epub 2009 Apr 21.

13.

Dual variation in SCN5A and CACNB2b underlies the development of cardiac conduction disease without Brugada syndrome.

Hu D, Barajas-Martinez H, Nesterenko VV, Pfeiffer R, Guerchicoff A, Cordeiro JM, Curtis AB, Pollevick GD, Wu Y, Burashnikov E, Antzelevitch C.

Pacing Clin Electrophysiol. 2010 Mar;33(3):274-85. doi: 10.1111/j.1540-8159.2009.02642.x. Epub 2009 Dec 16.

14.

SCN5A mutation associated with acute myocardial infarction.

Oliva A, Hu D, Viskin S, Carrier T, Cordeiro JM, Barajas-Martinez H, Wu Y, Burashnikov E, Brugada R, Rosso R, Guerchicoff A, Pollevick G, Pascali VL, Antzelevitch C.

Leg Med (Tokyo). 2009 Apr;11 Suppl 1:S206-9. doi: 10.1016/j.legalmed.2009.02.044. Epub 2009 Apr 2.

15.

Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome.

Delpón E, Cordeiro JM, Núñez L, Thomsen PE, Guerchicoff A, Pollevick GD, Wu Y, Kanters JK, Larsen CT, Hofman-Bang J, Burashnikov E, Christiansen M, Antzelevitch C.

Circ Arrhythm Electrophysiol. 2008 Aug;1(3):209-18. doi: 10.1161/CIRCEP.107.748103. Erratum in: Circ Arrhythm Electrophysiol. 2008 Aug;1(3):e2. Hofman-Bang, Jacob [added].

16.

Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation.

Ravn LS, Aizawa Y, Pollevick GD, Hofman-Bang J, Cordeiro JM, Dixen U, Jensen G, Wu Y, Burashnikov E, Haunso S, Guerchicoff A, Hu D, Svendsen JH, Christiansen M, Antzelevitch C.

Heart Rhythm. 2008 Mar;5(3):427-35. doi: 10.1016/j.hrthm.2007.12.019. Epub 2008 Feb 4.

17.

Genetic predisposition and cellular basis for ischemia-induced ST-segment changes and arrhythmias.

Hu D, Viskin S, Oliva A, Cordeiro JM, Guerchicoff A, Pollevick GD, Antzelevitch C.

J Electrocardiol. 2007 Nov-Dec;40(6 Suppl):S26-9.

18.

Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction.

Hu D, Viskin S, Oliva A, Carrier T, Cordeiro JM, Barajas-Martinez H, Wu Y, Burashnikov E, Sicouri S, Brugada R, Rosso R, Guerchicoff A, Pollevick GD, Antzelevitch C.

Heart Rhythm. 2007 Aug;4(8):1072-80. Epub 2007 Apr 10.

19.

A novel mutation in KCNQ1 associated with a potent dominant negative effect as the basis for the LQT1 form of the long QT syndrome.

Aizawa Y, Ueda K, Scornik F, Cordeiro JM, Wu Y, Desai M, Guerchicoff A, Nagata Y, Iesaka Y, Kimura A, Hiraoka M, Antzelevitch C.

J Cardiovasc Electrophysiol. 2007 Sep;18(9):972-7. Epub 2007 Jul 26.

20.

Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death.

Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP Jr, Burashnikov E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haïssaguerre M, Schimpf R, Borggrefe M, Wolpert C.

Circulation. 2007 Jan 30;115(4):442-9. Epub 2007 Jan 15.

Supplemental Content

Loading ...
Support Center